XBiotech (4XB) Stock Statistics & Valuation Metrics
Total Valuation
XBiotech has a market cap or net worth of CHF 47.22M. The enterprise value is -CHF 43.20T.
- Market Cap
- CHF 47.22M
- Enterprise Value
- -CHF 43.20T
Share Statistics
XBiotech has 30,487,732 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 30,487,732
- Owned by Insiders
- 13.75%
- Owned by Institutions
- 1.02%
Financial Efficiency
XBiotech’s return on equity (ROE) is -0.32 and return on invested capital (ROIC) is -39.17%.
- Return on Equity (ROE)
- -0.32
- Return on Assets (ROA)
- -0.30
- Return on Invested Capital (ROIC)
- -39.17%
- Return on Capital Employed (ROCE)
- -0.39
- Revenue Per Employee
- 0
- Profits Per Employee
- -523.45K
- Employee Count
- 87
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of XBiotech is -1.27. XBiotech’s PEG ratio is 0.02.
- PE Ratio
- -1.27
- PS Ratio
- 0.00
- PB Ratio
- 0.45
- Price to FCF
- -1.40
- Price to Operating Cash Flow
- -1.41
- PEG Ratio
- 0.02
Income Statement
In the last 12 months, XBiotech had revenue of 0 and earned -45.54M in profits. Earnings per share was -1.49.
- Revenue
- 0
- Gross Profit
- -1.69M
- Operating Income
- -55.69M
- Pretax Income
- -45.30M
- Net Income
- -45.54M
- EBITDA
- -43.53M
- Earnings Per Share (EPS)
- -1.49
Cash Flow
In the last 12 months, operating cash flow was -40.70M and capital expenditures -141,000, giving a free cash flow of -40.84M billion.
- Operating Cash Flow
- -40.70M
- Free Cash Flow
- -40.84M
- Free Cash Flow per Share
- -1.34
Dividends & Yields
XBiotech pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -71.25%
- Earnings Yield
- -78.74%
Stock Price Statistics
- Beta
- -0.18
- 52-Week Price Change
- 0.00%
- 50-Day Moving Average
- 1.79
- 200-Day Moving Average
- 1.79
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- 67
Financial Position
XBiotech as a current ratio of 16.01, with Debt / Equity ratio of 0.00%
- Current Ratio
- 16.01
- Quick Ratio
- 16.01
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 2.88
- Interest Coverage Ratio
- -632.78
Taxes
In the past 12 months, XBiotech has paid 235.00K in taxes.
- Income Tax
- 235.00K
- Effective Tax Rate
- -0.01
Enterprise Valuation
XBiotech EV to EBITDA ratio is 1.26, with an EV/FCF ratio of 1.28.
- EV to Sales
- 0.00
- EV to EBITDA
- 1.26
- EV to Free Cash Flow
- 1.28
- EV to Operating Cash Flow
- 1.28
Balance Sheet
XBiotech has CHF 109.53M in cash and marketable securities with CHF 0.00 in debt, giving a net cash position of CHF 109.53M billion.
- Cash & Marketable Securities
- CHF 109.53M
- Total Debt
- CHF 0.00
- Net Cash
- CHF 109.53M
- Net Cash Per Share
- CHF 3.59
- Tangible Book Value Per Share
- CHF 4.21
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for XBiotech is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -60.25%
Scores
- Smart Score
- 4
- AI Score
- ―